Loading…
Employees: 1,920
Size CK Life Sciences International (Holdings) (0775.HK) is a Hong Kong Health Care company (Pharmaceuticals: Other) with a market value of $644M, the 695th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$0.53 on 6 Nov 2026.
Performance Over six months the shares fell 30.0%, against -19.4% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 0.5% over the last twelve months (peer median -1.8%); the operating margin is -0.2% (peer median 9.5%).
Valuation It trades at 2.1× enterprise value to sales against a peer median of 3.1× (5th cheapest of 18).
Capital Return on invested capital runs 5.6 points below its cost of capital (5.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$5.52B | HK$5.41B | HK$5.52B | HK$5.32B | HK$5.28B |
| Revenue growth | — | -2% | +4% | +1% | — |
| Gross profit | HK$739M | HK$785M | HK$945M | HK$948M | HK$988M |
| EBITDA | HK$76.3M | -HK$49.4M | HK$159M | HK$319M | HK$321M |
| Net income | -HK$64.7M | -HK$187M | -HK$127M | HK$17.2M | HK$132M |
| Free cash flow | n/a | -HK$278M | -HK$139M | -HK$59.3M | HK$13.2M |
| Capital expenditure | n/a | HK$248M | HK$199M | HK$292M | HK$217M |
| Total debt | n/a | HK$6.62B | HK$6.10B | HK$5.93B | HK$5.95B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 0775.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.9% | -7.1% | 6th highest of 21 |
| 6-month return | -30.0% | -19.4% | 5th lowest of 21 |
| Distance from 52-week high | -48.5% | -37.2% | 6th lowest of 21 |
| Revenue growth (TTM) | +0.5% | -1.8% | 10th highest of 20 |
| Operating margin | -0.2% | 9.5% | 4th lowest of 19 |
| EV / Sales | 2.1× | 3.1× | 5th cheapest of 18 |
| ROIC minus cost of capital | -5.6 pp | -0.2 pp | 5th lowest of 19 |
| Net debt / EBITDA | 82.5× | -2.3× | most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CK Life Sciences International (Holdings) 0775.HK | Hong Kong | $644M | -30% | 0% | 0% | 2.1× | n/a | n/a |
| ABA Chemicals 300261.SZ | China | $641M | -27% | -16% | -23% | 5.2× | n/a | n/a |
| Hangzhou Minsheng Healthcare 301507.SZ | China | $624M | -21% | +21% | 11% | 4.1× | 20.4% | +12.1% |
| ArriVent BioPharma AVBP | United States | $673M | -54% | n/a | n/a | n/a | n/a | n/a |
| Lanzhou Foci Pharmaceutical 002644.SZ | China | $582M | -9% | +3% | 5% | 3.6× | 24.3% | +6.5% |
| Hunan Hansen Pharmaceutical 002412.SZ | China | $582M | +10% | -4% | 21% | 3.4× | 3.0% | +7.0% |
| Lionco Pharmaceutical 603669.SS | China | $581M | +21% | -6% | -17% | 10.2× | n/a | n/a |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $713M | -16% | -28% | -25% | 2.0× | n/a | n/a |
| Brother Enterprises 002562.SZ | China | $716M | -28% | +8% | 4% | 1.6× | 4.9% | +13.5% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $719M | -21% | -18% | 25% | n/a | n/a | n/a |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $756M | -17% | -14% | 22% | 3.7× | 1.8% | +4.8% |
| Sirio Pharma 300791.SZ | China | $790M | -12% | -9% | 1% | 1.6× | 14.7% | +15.6% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $801M | -14% | -12% | 3% | 2.5× | 3.6% | -1.3% |
| PharmaNutra PHN.MI | Italy | $808M | -18% | +18% | 21% | 5.1× | 4.0% | +18.5% |
| TSI 603262.SS | China | $909M | -41% | +3% | 14% | 5.0× | 25.8% | +13.4% |
| Myung in Pharm 317450.KS | South Korea | $455M | -24% | +7% | 35% | 2.1× | -14.7% | +8.9% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $952M | -35% | +30% | 15% | 2.3× | n/a | n/a |
| Tibet Aim Pharm 002826.SZ | China | $427M | -23% | +13% | 14% | 3.1× | 1.3% | +1.0% |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $999M | -16% | -14% | 8% | 3.0× | n/a | n/a |
| Applied Nutrition APN.L | United Kingdom | $1.01B | +42% | +24% | n/a | n/a | n/a | n/a |
| Boiron BOI.PA | France | $391M | -31% | -2% | 5% | 0.7× | -0.3% | -0.5% |